Precision Neuroscience raises $250M to take its thin-film brain interface toward market
The Series D values the maker of the Layer 7 Cortical Interface at about $1 billion and brings its total funding to $430 million.
Precision Neuroscience has closed a $250 million Series D. Pershing Square, the Ackman Oxman Institute and an unnamed life-sciences fund co-led the round. Precision’s total funding is now about $430 million, and reports put its valuation at roughly $1 billion.
What Precision builds
Precision’s Layer 7 Cortical Interface is a film thinner than a human hair with 1,024 electrodes on it. It rests on the brain’s surface instead of piercing it. Surgeons slide it in through a narrow “micro-slit” in the skull, so the procedure is less invasive than the open-skull operations used for older brain implants.
In 2025, Layer 7 received FDA 510(k) clearance for temporary use of up to 30 days, mainly to map brain activity during neurosurgery. The company says the new money will expand its clinical program and move Layer 7 through the next FDA reviews. The goal is longer-term use as a brain-computer interface for people with paralysis. It will also start building the sales and support needed for commercialization.
Why it matters
- Different approaches are attracting money. Neuralink and Paradromics push electrodes into brain tissue. Synchron goes through blood vessels. Precision rests on the surface. Large rounds for all of them suggest investors don’t yet know which approach will win.
- Commercialization is starting. Money for sales and support infrastructure shows BCI companies are now planning for real customers, not just trials.
Learn more: ECoG · Invasive vs. non-invasive BCIs · Precision Neuroscience in the Directory